In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

Executive Summary

South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.

You may also be interested in...



FDA’s SaMD/SiMD Guidance Could Mean Documentation Headaches For Some Software Makers, Attorney Says

A long-awaited draft guidance from the US agency delineates which medical software devices will need additional documentation based on risk – but it could also mean more work for some manufacturers.

FDA Issues 5-Point Action Plan For Artificial Intelligence/Machine Learning-Based SaMD

A new guidance document and a promise to hold a public workshop are just two commitments made by the US agency in a 12 January action plan aimed at AI/ML-based software as a medical device.

GAO/NAS Report On AI In Health Care Critical Of FDA Slowness On SaMD Rulemaking

A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV147677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel